Grail grabs $900M-plus in Se­ries B; Al­ny­lam’s givosir­an makes PRIME time

→ Men­lo Park, CA-based Grail has banked more than $900 mil­lion in its first close of a big Se­ries B led by Arch Ven­ture Part­ners. J&J In­no­va­tion made a big con­tri­bu­tion, drawn by the up­starts plans to rev­o­lu­tion­ize the ear­ly de­tec­tion and treat­ment of can­cer. “We en­vi­sion a glob­al com­mu­ni­ty that ben­e­fits from ear­ly-stage can­cer de­tec­tion where few­er in­di­vid­u­als face the an­guish of late-stage di­ag­no­sis and dev­as­tat­ing out­comes,” said Jeff Hu­ber, Grail’s CEO. “I be­lieve that Grail’s ap­proach lever­ag­ing high-in­ten­si­ty se­quenc­ing, pop­u­la­tion-scale clin­i­cal stud­ies, and state of the art Com­put­er Sci­ence and Da­ta Sci­ence is un­par­al­leled in the field of can­cer de­tec­tion. Our team made tremen­dous progress in 2016 and I look for­ward to ad­di­tion­al clin­i­cal and strate­gic mile­stones.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER